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Mesenchymal stem cells (MSCs) are efficacious in a variety of intractable diseases. While bone marrow (BM)-
derived MSCs (BM-MSCs) have been widely investigated, MSCs from other tissue sources have also been 
shown to be effective in several autoimmune and inflammatory disorders. In the present study, we simultane-
ously assessed the therapeutic efficacy of human BM-MSCs, as well as MSCs isolated from adipose tissue 
(Ad-MSCs) and umbilical cord Wharton’s jelly (UC-MSCs), in experimental autoimmune encephalomyelitis 
(EAE), an animal model for multiple sclerosis (MS). Prior to in vivo experiments, we characterized the 
phenotype and function of all three MSC types. We show that BM-MSCs were more efficient at suppress-
ing the in vitro proliferation of mitogen or antigen-stimulated T-cell responses compared to Ad-MSCs and 
UC-MSCs. Notably BM-MSCs induced the differential expression of cytokines from normal and stimulated 
T-cells. Paradoxically, intravenous transplantation of BM-MSCs into C57Bl/6 mice with chronic progressive 
EAE had a negligible effect on the disease course, even when multiple MSC injections were administered over 
a number of time points. In contrast, Ad-MSCs had the most significant impact on clinical and pathological dis-
ease outcomes in chronic progressive and relapsing–remitting EAE models. In vivo tracking studies revealed 
that Ad-MSCs were able to migrate to the central nervous system (CNS), a property that most likely correlated 
with their broader expression of homing molecules, while BM-MSCs were not detected in this anatomic region. 
Collectively, this comparative investigation demonstrates that transplanted Ad-MSCs play a significant role in 
tissue repair processes by virtue of their ability to suppress inflammation coupled with their enhanced ability to 
home to the injured CNS. Given the access and relatively ease for harvesting adipose tissue, these data further 
implicate Ad-MSCs as a cell therapeutic that may be used to treat MS patients.
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disease process. While these have been shown to alter the 
disease course, they are, however, only partially effective 
and have little impact on disease progression (41). Thus, 
there is a clear need to find new therapeutic approaches 
to treat this severely debilitating disease. Stem cell thera-
pies, including those based on transplantation of multipo-
tent stromal cells [also known as mesenchymal stem cells 
(MSCs)], have the potential to act as immunomodulatory 
as well as neuroprotective agents and therefore represent 
a promising novel cell therapeutic for MS.
MSCs were originally identified from the bone mar-
row (BM), where they represent only a minor fraction of 
the total number of BM cells (58). Although the in vivo 
INTRODUCTION
Although the precise mechanisms attributed to the ini-
tiation of multiple sclerosis (MS) have yet to be clearly 
elucidated, current consensus suggests that the disease 
is maintained by autoreactive T-cells that target proteins 
expressed predominantly on the myelin sheath and, to a 
lesser extent on axons, resulting in central nervous sys-
tem (CNS) tissue injury (52). Despite early attempts at 
repair, accumulating axonal and neuronal damage due to 
chronic neuroinflammation and neurodegeneration ulti-
mately leads to increasing and permanent neurological 
dysfunction (24). A number of therapeutic approaches 
have been targeted towards the immune component of the 
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identity of MSCs is still under debate (16,54), these cells 
play an important role in supporting hematopoiesis and 
maintaining homeostasis within the BM niche (74). In 
addition to the relative ease in which these cells can be 
isolated and expanded ex vivo, MSCs possess a number 
of functional properties pertinent in a therapeutic trans-
plantation setting. Extensive investigations into their 
immunomodulatory properties have shown that MSCs 
can inhibit T-cell (22,43), B-cell (15), and antigen- 
presenting cell (8) function; are protected from cytotoxic 
T-cell-mediated lysis (63); and can modulate the actions 
of T-regulatory cells (Tregs) (21). Systemically infused 
MSCs preferentially home to inflamed and injured tis-
sues (38) and induce clinical recovery via a number of 
mechanisms, such as the suppression of inflammatory 
responses, exertion of potent antioxidant effects, and the 
secretion of trophic factors capable of stimulating endog-
enous repair pathways (68). Further corroborating these 
observations, MSC transplantation can be effective at 
reducing inflammatory responses in experimental animal 
models of myocardial infarction (47), diabetes (26), rheu-
matoid arthritis (1), and lupus nephritis (11).
The potential benefits of MSC treatment in MS have 
been highlighted by a series of transplantation studies 
in experimental autoimmune encephalomyelitis (EAE). 
Two early reports demonstrated that systemic transplan-
tation of BM-MSCs can modulate immune responses 
to induce peripheral tolerance and ameliorate disease 
(29,75). These peripheral effects have since been con-
firmed in other studies following intravenous (IV) and 
intraperitoneal (IP) delivery of MSCs (3,14,31,61,62). 
While several groups report that a small number of MSCs 
of either mouse (14,39) or human origin (3,32) are capa-
ble of homing to the CNS to exert in situ immunomodu-
latory and neuroprotective effects, there is little evidence 
for their long-term engraftment. 
Since their identification within the BM compartment, 
MSCs have been isolated from almost every tissue in the 
body (18). Despite their similarities, comparative analy-
ses on tissue-specific MSCs have revealed differences 
that may be relevant to their ability to modulate immune 
responses (9,37). To date, a comparative study of the 
potential of tissue-specific MSCs to inhibit autoimmune-
mediated demyelination has not yet been carried out. 
Here, we report on the characterization of human MSCs 
isolated from three different tissues, BM, adipose tissue 
(Ad), and umbilical cord Wharton’s jelly (UC), with a 
particular focus on comparing their immunomodulatory 
effects in vitro. The therapeutic efficacy of these three 
MSC populations was then evaluated using recombinant 
myelin oligodendrocyte glycoprotein (rMOG)-induced 
EAE, a model of MS in which both T- and B-cells con-
tribute to disease pathogenesis.
MATERIALS AND METHODS
Mice
C57Bl/6 mice were purchased from Monash University 
Animal Services. Nonobese diabetic (NOD)/Lt mice 
were purchased from the Walter and Eliza Hall Institute 
animal breeding facility (Melbourne, Australia). MOG 
T-cell receptor (TCR) transgenic (2D2) mice and mac-
rophage colony-stimulating factor receptor (Cfms)-green 
fluorescent protein (GFP) mice were bred at the Monash 
University Animal Services breeding facility. All mice 
were bred and maintained under pathogen-free conditions.
Mesenchymal Stem Cell Culture
Normal or enhanced green fluorescent protein (e)GFP-
expressing human BM-MSCs purchased from the Tulane 
Center for Stem Cell Research and Regenerative Medicine 
(Tulane University, New Orleans, LA, USA) were cul-
tured in a medium consisting of aMEM supplemented 
with 16.5% FBS, 2 mM l-glutamine, 100 U/ml penicil-
lin, and 100 μg/ml streptomycin (all from Invitrogen, 
Carlsbad, CA, USA). Cells were seeded at a density of 
60 cells/cm2 in tissue culture flasks (BD Biosciences, Frank- 
lin Lakes, NJ, USA), and medium was changed every 
3–4 days. BM-MSCs were passaged upon reaching ~80% 
confluence (typically after 10–12 days of culture) using 
0.25% trypsin-EDTA (Invitrogen). Human Ad-MSCs 
and UC-MSCs purchased from ScienCell (Carlsbad, CA, 
USA) were cultured in medium consisting of aMEM con-
taining 5% FBS, 100 U/ml penicillin, 100 μg/ml strepto- 
mycin, and 1% MSC growth supplement (ScienCell). 
Cells were seeded in a flask precoated with 2 μg/cm2 poly-
l-lysine (Sigma-Aldrich, St. Louis, MO, USA) at a density 
of 5,000 cells/cm2 and passaged when they reached 90% 
confluence (typically after 3 days) using 0.25% trypsin-
EDTA. For some in vitro experiments, MSCs were cul-
tured in the presence of human recombinant interferon 
(IFN)-g (R&D Systems, Minneapolis, MN, USA) at 
10 ng/ml for the final 72 h of culture. 
Flow Cytometry
Phenotypic analysis by single color flow cytometry 
was performed by staining 0.5 ´  106 cells with primary 
antibodies for 20 min at 4°C. Where applicable, cells 
were then stained with a goat anti-mouse or goat anti-
rat Alexa Fluor 647 secondary antibody for 20 min at 
4°C. The relevant isotype control antibody was used as 
a negative control. Data acquisition was performed using 
a FACSCalibur Flow Cytometer (BD Biosciences), and 
data were analyzed using Gatelogic Software (Inivai 
Technologies, Mentone, Victoria, Australia). Primary 
antibodies were purchased from BD Biosciences, and sec-
ondary antibodies were purchased from Invitrogen. Cell 
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surface expression of adhesion molecules was assessed 
using a Human Cell Surface Marker Screening Panel test 
kit kindly provided by BD Biosciences. 
Gene Expression Analysis
Total RNA was extracted from 1 ´  106 MSCs at pas-
sages 3 and 5, using a High Pure RNA Isolation Kit (Roche, 
Indianapolis, IN, USA) as per the manufacturer’s instruc-
tions. cDNA was prepared from 0.5 μg of total RNA using 
a SuperScript III First-Strand Synthesis System RT-PCR 
Kit and oligo (dT) primers (Invitrogen). PCR was per-
formed using Taq DNA Polymerase (Invitrogen) with 1 μl 
cDNA and primer pairs for human chemokine receptors 
(10,28) under the following cycling conditions: 94°C for 
5 min and then 35 cycles of 94°C for 1 min, 55°C for 45 s, 
and 72°C for 1 min followed by 72°C for 10 min. The 
PCR products were resolved by electrophoresis in 2% 
agarose gels and the bands visualized under UV light.
EAE Induction and Cell Transplantation
EAE was induced in 10- to 12-week-old female 
C57Bl/6 or NOD/Lt mice with the extracellular domain 
of mouse recombinant (r)MOG (amino acid residues 1– 
117 of the mature protein) (6) as previously described 
(56). For MSC transplantation, cells were injected via the 
lateral tail vein or into the peritoneal cavity in a volume 
of 200 μl on the days indicated. Control mice received 
injections of equal volumes of phosphate-buffered saline 
(PBS, Invitrogen). Mice were monitored daily, and clini-
cal scores were assigned according to an arbitrary clini-
cal scale as described (53). Mice were humanely killed 
upon reaching a clinical score of 4. All animal experi-
ments were carried out in accordance with animal ethics 
guidelines, as set out by the Monash University School of 
Biomedical Sciences Animal Ethics Committee.
T-Cell Proliferation Assays and Cytokine Production
Spleens were collected from normal C57Bl/6 mice, 
2D2 mice expressing the transgenic Va3.2/Vb11 TCR (7), 
or rMOG-immunized mice. Single cell suspensions were 
prepared in complete Roswell Park Memorial Institute 
(RPMI) medium containing 10% heat-inactivated FBS, 
2 mM l-glutamine, 100 U/ml penicillin,100 μg/ml strep-
tomycin (all from Invitrogen), 50 μM 2- mercaptoethanol 
(Sigma-Aldrich), and 1 mM sodium pyru-vate (Sigma-
Aldrich). Red blood cells were lysed in 3 mllysis buf-
fer (155 mM NH4CL, 10 mM KHCO3, 0.1 mM EDTA, 
Sigma-Aldrich) for 1 min, and then splenocytes were 
seeded in triplicate in 96-well, flat-bottommed micro-
titer plates (Nunc, Roskile, Denmark) at a concentration 
of 2.5 ´  105 cells per well. Splenocytes were cultured 
in medium alone or in the presence of either 20 μg/ml 
MOG35–55 (GL Biochem, Shanghai, China), 20 μg/ml 
rMOG, 800 ng/ml ionomycin, and 20 pg/ml phorbol 
myristate acetate (PMA, both from Sigma-Aldrich), or 
in wells precoated with 10 μg/ml anti-CD3 and 10 μg/
ml anti-CD8 antibodies (both from BD Biosciences). Cells 
were incubated at 37°C for 72 h with the addition of 
1 μCi/well [3H]thymidine (Perkin Elmer, Waltham, MA, 
USA) for the last 18 h of culture. Cells were harvested 
onto filter mats (Perkin Elmer) and incorporated radio-
active nucleic acids counted using a Top Count NXT 
Scintillation Counter (Packard Biosciences, Meriden, CT, 
USA). For coculture experiments, MSCs were added at 
concentrations ranging from 0.002 to 0.25 ´  105 cells per 
well prior to the addition of 2.5 ´  105 splenocytes.
For analysis of cytokine production, 2.5 ´  106 2D2 sple-
nocytes were cultured in 24-well plates (BD Biosciences) 
for 48 h in medium alone or in the presence of 20 μg/
ml MOG35–55, to a final volume of 1 ml. For coculture 
experiments, 0.25 ´  106 MSCs, 500 μl MSC conditioned 
medium, or 500 μl control cell culture medium was 
added. Quantitative analysis of interleukin (IL)-2, IL-6, 
IL-10, IL-17A, IFN-g, and tumor necrosis factor (TNF)-a 
was performed using a mouse cytometric bead array kit 
(BD Biosciences) according to the manufacturer’s instruc-
tions. Acquisition of events was performed on a BD 
FACSCanto II Flow Cytometer and data analyzed and fit-
ted to a four-parameter logistic equation using the FCAP 
Array Software (Soft Flow, St. Louis Park, MN, USA). 
Anti-MOG Antibody Determination
Blood was collected at the end point of experiments by 
cardiac puncture and sera isolated. The antibody isotypes 
IgG, IgG1, IgG2a, IgG2b, IgG3, IgA, and IgM that specifi-
cally bound to rMOG were measured by ELISA. Briefly, 
flat-bottommed 96-well plates were coated with 100 μl 
of rMOG (5 μg/ml) in 0.05 M carbonate buffer (15 mM 
Na2CO3, 35 mM NaHCO3, pH 9.6; Sigma-Aldrich) over-
night at 4°C. Wells were blocked with Pierce protein-free 
blocking medium (Thermo Fischer Scientific, Rockford, 
IL, USA) supplemented with 1.5% normal goat serum for 
3 h at room temperature. For specific isotype antibody 
responses, serum was diluted as follows: 1/8,000 for IgG 
and IgG1, 1/50 for IgG2a, 1/2,000 for IgG2b, 1/200 for 
IgG3, 1/50 for IgA, and 1/100 for IgM. Serum from naive 
C57BL/6 mice was used as a negative control and the 
anti-MOG monoclonal antibody clone 8-18C5 (produced 
in-house by hybridoma) diluted to 5 μg/ml was used as 
a positive control. Antibody binding was revealed using 
horseradish peroxidase-conjugated goat anti-mouse iso-
type antibodies (Caltag Laboratories, Burlingame, CA, 
USA) diluted 1/2,000 or a polyvalent IgG,A,M antibody 
(Sigma-Aldrich) diluted 1/1,000. O-Phenylenediamine 
(Sigma-Aldrich) was used as a substrate and the reac-
tion performed according to the manufacturer’s protocol. 
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Optical density (OD) was measured at 492 nm on a 
Benchmark Plus Microplate Spectrophotometer (BioRad, 
Hercules, CA, USA).
Histological Analysis of CNS Tissue
For histological analysis of CNS tissue, the brain and 
spinal cord were dissected from mice and fixed in 10% 
formalin (Sigma-Aldrich). Sections (5 μm) were cut from 
paraffin-embedded tissue and stained with hematoxylin–
eosin, luxol fast blue, and Bielschowsky silver impregna-
tion to assess inflammation, demyelination, and axonal 
damage, respectively. Reagents for histological stain-
ing were purchased from Grale Scientific (Ringwood, 
Victoria, Australia).
Lentiviral Transduction of MSCs
The parental pWPI lentiviral plasmid, a second gen-
eration, self-inactivating, bicistronic lentiviral vector 
was obtained from Professor Didier Trono (Ecole Poly-
technique Federale de Lausanne). This vector back-
bone incorporates an elongation factor-1a promoter, 
an internal ribosomal entry site (IRES)-enhanced green 
fluorescent protein (eGFP) cassette, and the Woodchuck 
posttranslation regulatory element. Using standard molec-
ular biology techniques, the cDNA for firefly luciferase 
(fluc) was subcloned and blunt-end ligated upstream 
of the IRES-eGFP cassette generating the transfer vec-
tor pWPI-fluc-IRES-eGFP. Viral stocks were generated 
by transfecting pWPI-fluc-IRES-eGFP together with 
pSPAX2 and pMD.2G using Fugene6 (Roche) into 293T 
cells (ATCC CRL-11268; Manassas, VA, USA) as previ-
ously described (67). Typically, 0.5–1 ´  107 transducing 
units/ml of unconcentrated vector was generated in this 
manner. Nonmodified MSCs were transduced twice at a 
multiplicity of infection of 50 over a 48-h period with 
unconcentrated lentiviral supernatant diluted 1:2 with 
culture medium in the presence of 8 μg/ml protamine sul-
fate (Sigma-Aldrich). Transduction medium was replaced 
with fresh medium 16 h after each transduction. 
Bioluminescence Imaging
Animals were transplanted via the lateral tail vein 
with 1 ´  106 transduced MSCs. To image gene-modified 
cells, animals were injected IP with 200 μl d-luciferin 
(15 mg/ml in PBS, VivoGlo Luciferin, Promega, San Luis 
Obispo, CA, USA) on days 0, 2, 7, 14, 21, and 28 post-
cell injection. On these days, mice were anesthetized for 
10 min with 2.5% isoflurane prior to bioluminescence 
imaging, which was performed with an IVIS 200 system 
(Xenogen, Alameda, CA, USA). The fluc luminescent 
signal intensity was analyzed using Living Image 3.2 
Software (Xenogen). 
Tracking of GFP+ MSCs by PCR
Organs from EAE mice injected with BM-MSCs or 
Ad-MSCs overexpressing eGFP were dissected and 
genomic DNA extracted using a Gentra Puregene Tissue 
Kit (Qiagen, Venlo, Netherlands) according to the manu-
facturer’s instructions. PCR for eGFP was performed with 
Platinum Pfx DNA Polymerase (Invitrogen) and 100 ng 
of cDNA under the following cycling conditions: 94°C 
for 5 min and then 42 cycles of 94°C for 30 s, 64.9°C for 
30 s, and 68°C for 30 s followed by 68°C for 10 min. PCR 
for the housekeeping gene b-actin was performed with 
Platinum Taq DNA Polymerase (Invitrogen) and 100 ng of 
cDNA under the following cycling conditions: 94°C for 
2 min and then 32 cycles of 94°C for 30 s, 53°C for 30 s, and 
72°C for 1 min followed by 72°C for 10 min. Primer pairs 
were eGFP: 5¢-TACGGCAAGCTGACCCTGAAGTTC-3¢, 
5¢-CGTCGTCCTTGAAGAAGATGGTGCG-3¢; b-actin: 
5¢-GGCACCACACCTTCTACAATG-3¢, 5¢-CTGCTGC 
TGAAGCTGTAG-3¢. The PCR products were resolved 
by electrophoresis in 2% agarose gels, and the bands 
were visualized under UV light. DNA from cFMS-GFP 
mice and uninjected mice were positive control (+ve) and 
negative controls, respectively.
Statistical Analysis
Data are presented as the mean ± standard error of the 
mean (SEM). All statistical analyses were performed 
using Prism 5.04 (Graphpad Software, San Diego, CA, 
USA). Significant differences between two groups were 
determined using an unpaired Student’s t test. Statistical 
analysis of three or more groups was performed using 
one-way ANOVA with Kruskal–Wallis and Dunn’s 




Flow cytometric analysis was used to examine the 
expression of cell surface markers by MSCs. Consistent 
with the minimal criteria proposed by Dominici et al. 
(23), BM-MSCs, Ad-MSCs, and UC-MSCs expressed the 
canonical MSC antigens CD73, CD90, and CD105 but 
lacked expression of the hematopoietic markers CD45, 
CD34, CD11b, and CD19 (data not shown). HLA-DR 
(MHC class II) was not constitutively expressed but could 
be induced by IFN-g stimulation (Fig. 1). All three MSC 
types expressed HLA-ABC (MHC class I) but lacked 
expression of the costimulatory molecules B7-H2, CD28, 
CD40, CD80, and CD86. Notably CD47, which interacts 
with signal regulatory protein a (SIRPa) to negatively 
regulate phagocytosis (51), was highly expressed on all 
three MSC types.
TISSUE-SPECIFIC MSCs FOR TREATMENT OF MS 1413
BM-MSCs Suppress T-Cell Proliferation  
More Efficiently Than Ad-MSCs and UC-MSCs
The immunomodulatory effects exerted by MSCs rep-
resent an important mechanism by which these cells can 
mediate clinical recovery in experimental animal models 
(68). Given the central role of T-cells in EAE pathogen-
esis (52), we investigated the immunosuppressive poten-
tial of MSCs by simultaneously comparing their ability 
to inhibit T-cell proliferative responses under various in 
vitro conditions. Splenocytes from C57Bl/6 mice stimu-
lated with T-cell mitogens were cocultured with increas-
ing numbers of MSCs, and then their proliferation was 
analyzed after 72 h by [3H]thymidine incorporation. 
BM-MSCs had a dramatic effect on the proliferation 
of PMA/ionomycin activated splenocytes, resulting in 
greater than 90% inhibition of T-cell proliferation for 
all four MSC/splenocyte ratios tested (Fig. 2A). A dose-
dependent effect was observed following the addition 
of either Ad-MSCs or UC-MSCs, as demonstrated by 
decreasing T-cell proliferation with increasing concentra-
tions of MSCs. At the lowest ratio of 1:1250, BM-MSCs 
suppressed T-cell proliferation by at least 90%, while 
the relative suppression by Ad-MSCs and UC-MSCs 
was only 47% and 22%, respectively. Congruent with 
these observations, BM-MSCs were more efficient at 
suppressing TCR-dependent T-cell proliferation driven 
by the addition of anti-/CD28 antibodies (Fig. 2B). To 
assess whether MSCs could also inhibit autoantigen- 
specific T-cell responses in vitro, we used splenocytes 
from 2D2 mice that express the transgenic Va3.2/Vb11 
TCR specific for the MOG35–55 peptide in the context of 
I-Ab (7). MSCs suppressed the proliferation of 2D2 sple-
nocytes stimulated with MOG35–55 in a dose-dependent 
manner, with BM-MSCs again inhibiting T-cell prolif-
erative responses more efficiently compared to Ad-MSCs 
and UC-MSCs (Fig. 2C). 
Soluble Factors Secreted by BM-MSCs  
Modulate Cytokine Production
To assess whether MSCs could modulate the produc-
tion of cytokines that are relevant to EAE pathogenesis, 
supernatants were collected from cocultures of MSCs 
and MOG35–55-stimulated 2D2 splenocytes and cytokines 
quantified by cytometric bead array. Splenocytes cultured 
in the presence of MSCs produced significantly lower 
amounts of the Th1 cytokines IFN-g and IL-2 (Fig. 3A). 
Secretion of IL-17A was also significantly inhibited by 
BM-MSCs and Ad-MSCs; however, there was no change 
in IL-17A secretion when splenocytes were cocultured with 
UC-MSCs. Interestingly, while the presence of Ad-MSCs 
or UC-MSCs led to a reduction in TNF-a secretion, 
BM-MSCs had no effect on the secretion of this cytokine. 
Increased production of IL-6 and IL-10 was also observed 
when splenocytes were cocultured with BM-MSCs. 
Figure 1. Phenotypic profile of MSCs. Mesenchymal stem 
cells (MSCs) from bone marrow (BM), adipose tissue (Ad), 
and umbilical cord (UC) were cultured in the absence or pres-
ence of 10 ng/ml interferon (IFN)-g for 72 h, and cell sur-
face expression of human leukocyte antigen (HLA)-DR was 
examined by flow cytometry. Cell surface expression of other 
antigens was examined under standard culture conditions. 
Representative histograms of two independent experiments 
are shown in gray. Isotype controls are indicated by the black 
curve. B7-H2, inducible T-cell costimulator ligand; CD, clus-
ter of differentiation.
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Likewise, when we assessed the levels of IL-6, TNF-a, 
and IL-10 produced by unstimulated splenocytes, a dra-
matic increase in the production of these cytokines was 
observed in the presence of BM-MSCs only (Fig. 3B). 
Ad-MSCs or UC-MSCs did not elicit such a response. In 
addition to cell–cell contact mechanisms, MSCs can mod-
ulate immune responses through the secretion of soluble 
factors (22,62,71). Conditioned medium from confluent 
cultures of BM-MSCs was therefore added to unstimu-
lated or MOG35–55-stimulated splenocytes to determine if 
the increase in TNF-a, IL-6, and IL-10 was due to the 
release of soluble factors. We found that production of all 
three cytokines was significantly increased in the presence 
of BM-MSC conditioned medium, but not in the presence 
of control culture medium or conditioned medium from 
cultures of Ad-MSCs or UC-MSCs (Fig. 3C). 
BM-MSC Transplantation Does Not Have  
an Enhanced Therapeutic Effect on the  
Clinical Course in Chronic Progressive EAE
To compare the therapeutic effect of tissue-specific 
MSCs in vivo, we induced chronic progressive EAE by 
immunizing C57Bl/6 mice with the extracellular domain 
of rMOG. Three IV injections of 1 ´  106 MSCs were then 
administered prior to the onset of clinical signs on days 
8, 10, and 12 post-disease induction. There was an overall 
reduction in the daily mean clinical score of mice that 
received BM-MSCs, Ad-MSCs, or UC-MSCs compared 
to PBS injected controls; however, no difference between 
the different MSC-treated groups was observed (Fig. 4A). 
Notably, cumulative and maximal disease scores were 
significantly reduced in Ad-MSC- and UC-MSC-treated 
animals in comparison to the PBS-injected mice (Table 1). 
When splenocytes from EAE mice were restimulated 
in vitro with rMOG, the proliferative response was sig-
nificantly reduced for mice receiving MSCs compared 
to PBS controls (Fig. 4B) and no difference between the 
three MSC types was found. A similar reduction in T-cell 
proliferative responses was also observed upon restimula-
tion with anti-CD3/CD28 antibodies (Fig. 4C), indicating 
that MSC suppression was not limited to antigen-specific 
T-cell clones. Analysis of serum rMOG-specific antibody 
responses revealed no difference between MSC-treated 
mice and controls (Fig. 4D). 
To determine if MSC administration could impact on 
the clinical course of disease once immune-mediated dam-
age had already been established within the CNS, 1 ´  106 
MSCs were injected after the onset of clinical symptoms 
on days 12, 14, and 16 post-disease induction. In contrast 
to the previous treatment protocol, no beneficial effect 
was observed when MSCs were administered at these 
later time points (Fig. 5A). Given that treatment prior 
Figure 2. MSCs inhibit T-cell proliferation. C57Bl/6 splenocytes stimulated with either phorbol myristate acetate/ionomycin (PMA/I) 
(A) or anti-CD3/anti-CD28 antibodies (B) or 2D2 splenocytes stimulated with myelin oligodendrocyte glycoprotein (MOG)35–55 (C) were 
cultured in the presence of increasing doses of MSCs (expressed as MSC:splenocyte ratio). Proliferative responses were measured by 
[3H]thymidine incorporation and expressed as the mean counts per minute (CPM) + SEM of two independent experiments (n = 6 mice). 
*p < 0.05, **p < 0.01, ***p < 0.001 versus splenocytes without MSCs.
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to disease onset was more efficacious, we next assessed 
whether a single bolus injection of MSCs would have 
any beneficial effect in EAE mice. MSCs (2 ´  106) were 
administered IV on day 8 post-disease induction; how-
ever, there were no differences in disease onset or severity 
between MSC-treated mice and controls (Fig. 5B).
Ad-MSC Transplantation Attenuates  
Relapsing–Remitting EAE
As an adjunct to the chronic progressive EAE studies, 
we further examined the therapeutic potential of Ad-MSCs 
in a relapsing–remitting model (Fig. 6). Implementing 
a similar treatment protocol, 1 ´  106 Ad-MSCs or PBS 
were administered IV to NOD/Lt mice on days 8, 10, and 
12 post-rMOG immunization. Intriguingly, Ad-MSCs 
had a more profound effect on the development of 
EAE in this animal model, with a marked reduction in 
the clinical and maximum scores as well as a delay in 
the disease onset (Fig. 6A and Table 2). Given that IP. 
delivery of MSCs has previously been shown to amelio-
rate EAE through suppressing immune responses in the 
periphery (31,61,62), we also assessed the effect of high-
dose IP injections of Ad-MSCs. When 5 ´  106 Ad-MSCs 
were delivered on days 8, 10, and 12, there was an even 
greater amelioration of the disease compared to adminis-
tration of low-dose IV injections (Fig. 6B and Table 2). 
Consistent with the clinical data, hematoxylin and eosin 
staining of spinal cord sections showed a reduction in 
the inflammatory infiltration in Ad-MSC-treated mice 
compared to controls (Fig. 6C, F), which corresponded 
with a decrease in demyelination (Fig. 6D, G) and axonal 
damage (Fig. 6E, H).
Figure 3. BM-MSCs modulate cytokine production by autoantigen-stimulated splenocytes. Supernatants were collected from cocul-
tures of 2D2 splenocytes and MSCs or 2D2 splenocytes and MSC conditioned medium (CM) after 48 h, and cytokines were quantified 
by cytometric bead array. (A) MOG35–55-stimulated splenocytes cultured with MSCs at a ratio of 1:10. (B) Unstimulated splenocytes 
cultured with MSCs at a ratio of 1:10. (C) Unstimulated splenocytes cultured with CM or control culture medium (BM media or Ad/
UC media). Data represent the mean ± SEM of two independent experiments (n = 5 mice). *p < 0.05, **p < 0.01, ***p < 0.001 versus 
splenocytes without MSCs, ^p < 0.001 versus Ad-MSC and UC-MSC. IL, interleukin; TNF, tumor necrosis factor.
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Potential Molecular Trafficking Mechanisms Vary 
Between Tissue-Specific MSCs
In order to identify any cell-specific differences that 
may explain the discrepancy between the in vitro and in 
vivo immunomodulatory effect of BM-MSCs, we first 
examined the expression of molecules that may influence 
their in vivo trafficking. Extensive profiling of cell sur-
face adhesion molecules by flow cytometry is summa-
rized in Table 3. These results showed that, under standard 
culture conditions, all three MSCs lacked expression of 
molecules involved in selectin-mediated cellular migra-
tion, including E-selectin (CD62E), L-selectin (CD62L), 
P-selectin (CD62P), and P-selectin glycoprotein ligand 
(PSGL)-1 (CD162). Of the immunoglobulin superfamily 
cell adhesion molecules, activated-leukocyte cell adhe-
sion molecule (ALCAM; CD166) and melanoma cell 
adhesion molecule (MCAM; CD146) were expressed 
by all three MSCs; however, intercellular adhesion 
molecule-1 (ICAM-1; CD54) and vascular cell adhesion 
molecule-1 (VCAM-1; CD106) were expressed only 
by a subpopulation of Ad-MSCs and UC-MSCs. MSCs 
lacked integrin-aL (CD11a) and integrin-b2 (CD18) as 
well as integrin-aM (CD11b) and integrin-b2 (CD18), 
which heterodimerize to form lymphocyte function- 
associated antigen-1 (LFA-1) and macrophage 1 antigen 
(Mac-1), respectively. Although Ad-MSCs and UC-MSCs 
expressed integrin-a4 (CD49d) and integrin-b2 (CD29), 
the subunits that comprise very late antigen (VLA)-4 
BM-MSCs did not express integrin-a4. Consequently, 
BM-MSCs may not be capable of adhering to VCAM-1, 
a critical step involved in extravasation of cells into the 
CNS during EAE (13). The hyaluronic acid receptor 
CD44 was highly expressed by all three MSC types.
We next examined chemokine receptor mRNA expres-
sion by MSCs. All three MSC types expressed chemokine 
(C-C motif) receptor 6 (CCR6), CCR7, CCR11, chemokine 
(C-X-C motif) receptor 3 (CXCR3), CXCR6, and CXCR7 
(Table 4). Ad-MSCs and UC-MSCs also expressed CCR9 
and CCR10, while only Ad-MSCs expressed CCR1. 
CXCR4, which plays an important role in migration of 
cells to injured sites and has been shown to be expressed 
by MSCs (17,36), was in this case not detected. Previous 
studies have established that proinflammatory cytokines 
present during inflammation can modulate the expres-
sion of homing molecules (17,34,60). IFN-g, the sig-
nature cytokine of Th1 cells, is upregulated during the 
acute phase of EAE (57). Thus, we also compared the 
Figure 4. Multiple early MSC injections reduce EAE severity. 
C57Bl/6 mice were immunized with recombinant MOG (rMOG) 
and MSCs administered IV. (A) MSCs (1 ´  106) were injected 
on days 8, 10, and 12 postimmunization. Arrows, days of 
MSC injections. Proliferative response of splenic T-cells from 
MSC-treated mice and controls to rMOG (B) and anti-CD3/
anti-CD28 (C). (D) Serum rMOG-specific IgG, IgA, and IgM 
antibody responses from MSC-treated mice and controls. Data 
represent the mean ± SEM of two independent experiments 
(n = 9–10 mice). *p < 0.05 versus PBS controls.
Table 1. Clinical Outcome of Chronic Progressive EAE Mice Treated With MSCs
PBS BM-MSC Ad-MSC UC-MSC
Disease incidence 10/10 9/10 10/10 9/9
Mortality 3/10 2/10 0/10 0/9
Day disease onset 
 (range)
14.00 ± 0.45 
(11–15)
17.30 ± 1.69* 
(13–30)
15.60 ± 0.60 
(14–19)
17.44 ± 1.48* 
(16–28)
Maximum score 3.75 ± 0.28 3.00 ± 0.35 2.90 ± 0.16* 3.06 ± 0.06*
Cumulative score 51.25 ± 3.42 36.15 ± 6.77 33.25 ± 3.67** 36.06 ± 4.01*
Data represent mean ± SEM. *p < 0.05, **p < 0.01 versus PBS. EAE, experimental autoimmune encephalomyelitis; MSCs, mes-
enchymal stem cells; PBS, phosphate-buffered saline (control); BM, bone marrow; Ad, adipose tissue; UC, umbilical cord.
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Figure 5. MSCs have no effect when administered at disease onset or in a single dose. C57Bl/6 mice were immunized with rMOG and 
MSCs administered IV. (A) MSCs (1 ´  106) were injected on days 12, 14, and 16 postimmunization. (B) MSCs (2 ´  106) were injected 
on day 8 postimmunization. Data represent the mean ± SEM (n = 5 mice). Arrows, days of MSC injections. 
Figure 6. Ad-MSC transplantation suppresses relapsing–remitting EAE. NOD/Lt mice were immunized with rMOG and MSCs admin-
istered on days 8, 10, and 12 postimmunization. (A) Ad-MSCs (1 ´  106) were injected IV. (B) Ad-MSCs (5 ´  106) were injected IP. Arrows, 
days of Ad-MSC injections. Data represent the mean ± SEM (n = 4–6 mice). Representative spinal cord sections from mice injected IP with 
PBS (C–E) or Ad-MSCs (F–H) were stained with hematoxylin and eosin to detect inflammatory infiltrates (C, F), luxol fast blue to detect 
the degree of demyelination (D, G), and Bielschowsky silver stain to detect axonal damage (E, H). Original magnification: 400´. 
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expression of chemokine receptor mRNA by all three 
MSC types under standard culture conditions and fol-
lowing stimulation with IFN-g for 72 h. No qualitative 
changes in chemokine receptor expression were observed 
following stimulation of BM-MSCs or Ad-MSCs with 
IFN-g, while expression of CCR6 mRNA by UC-MSCs 
appeared to increase (Fig. 7). Given that long-term cell 
culture has been shown to decrease chemokine receptor 
expression and responsiveness to chemoattractants (36), 
we also analyzed mRNA from MSCs at passage 3 but 
found no difference in chemokine receptor expression 
profiles compared to passage 5 cells (data not shown). 
The Fate of Intravenously Transplanted MSCs
To compare the in vivo trafficking potential of BM- 
MSCs, Ad-MSCs, and UC-MSCs, we utilized a non-
invasive bioluminescent imaging technique to examine 
their biodistribution in NOD/Lt mice with relapsing– 
remitting EAE. MSCs were transduced with a bicistronic 
lentiviral vector encoding firefly luciferase (fluc) and 
eGFP and then transplanted IV into EAE mice during the 
first clinical relapse (day 27 post-disease induction). Bio-
luminescence fluc signals were predominantly detected 
in the lungs of EAE mice, indicating that all three MSC 
types had accumulated within the pulmonary capillaries. 
This fluc signal diminished rapidly during the following 
48 h and was undetectable 14 days post-cell injection 
(Fig. 8A, data not shown). No fluc signal was detected 
in the CNS or peripheral lymphoid tissues at any of the 
time points analyzed. 
As bioluminescence imaging may not have been 
sensitive enough to detect low numbers of trafficking 
MSCs, we next used a more sensitive technique based 
on the detection of eGFP+ cells by PCR to determine the 
tissue distribution of IV transplanted MSCs. Given that 
BM-MSCs lacked expression of integrin-a4, we com-
pared the trafficking of these cells to Ad-MSCs, which 
were found to express high levels of this important hom-
ing molecule. Transduced BM-MSCs and Ad-MSCs were 
injected IV into C57Bl/6 mice on day 7 post-disease induc-
tion, and the spleen, lymph nodes, brain, cerebellum, and 
spinal cord were examined by PCR for the presence of 
Table 2. Clinical Outcome of Relapsing–Remitting EAE Mice Treated With Ad-MSCs
PBS IV Ad-MSC IV PBS IP Ad-MSC IP
Disease incidence 5/5 5/6 6/6 3/4
Mortality 3/5 1/6 5/6 0/4
Day disease onset 
 (range)
11.80 ± 0.37 
(11–13)
22.33 ± 5.88* 
(13–51)
11.67 ± 0.80 
(10–15)
24.75 ± 9.00 
(13–51)
Maximum score 4.10 ± 0.56 2.42 ± 0.69 4.67 ± 0.33 1.50 ± 0.50**
Cumulative score 128.20 ± 22.78 61.17 ± 17.17 127.67 ± 14.98 42.00 ± 15.11**
Data represent mean ± SEM. *p < 0.05, **p < 0.01 versus PBS. 
Table 3. Cell Surface Adhesion Molecules Expressed by MSCs
Surface Marker BM-MSC Ad-MSC UC-MSC
Selectins
 CD62E (E-selectin) – – –
 CD62P (P-selectin) – – –
 CD62L (L-selectin) – – –
 CD162 (PSGL-1) – – –
Ig Superfamily CAMs
 ALCAM/ CD166 ++ ++ ++
 CEACAM-1/CD66a – – –
 CEACAM-8/CD66b – – –
 ICAM-1/CD54 – ++ ++
 ICAM-3/CD50 – – –
 MCAM/CD146 ++ ++ ++
 NCAM-1/CD56 – – ++
 PECAM-1/CD31 – – –
 VCAM-1/CD106 – + +
Integrins
 Integrin-a1/CD49a – ++ ++
 Integrin-a2/CD49b ++ ++ ++
 Integrin-a3/CD49c ++ ++ ++
 Integrin-a4/CD49d – ++ ++
 Integrin-a5/CD49e ++ ++ ++
 Integrin-a6/CD49f – – ++
 Integrin-a2b/CD41 – – –
 Integrin-aE/CD103 – – –
 Integrin-aL/CD11a – – –
 Integrin-aM/CD11b – – –
 Integrin-aV/CD51 – ++ ++
 Integrin-aX/CD11c – – –
 Integrin-b1/CD29 ++ ++ ++
 Integrin-t2/CD18 – – –
 Integrin-b3/CD61 – ++ ++
 Integrin-b4/CD104 – – –
 Integrin-b7 – – –
Other
CD44 ++ ++ ++
Cell surface expression of adhesion molecules by MSCs as assessed by 
flow cytometry. –, not detected; +, low (5–10%); ++, high (>80%). CD, 
cluster of differentiation; PSGL-1, P-selectin glycoprotein ligand-1; 
CAMs, cell adhesion molecules; ALCAM, activated-leukocyte cell 
adhesion molecule; CEACAM-1, carcinoembryonic antigen-related cell 
adhesion molecule-1; ICAM-1, intracellular adhesion molecule-1; 
MCAM, melanoma-cell adhesion molecule; NCAM, neural cell adhesion 
molecule; PECAM-1, platelet/endothelial cell adhesion molecule-1; 
VCAM-1, vascular cell adhesion molecule-1. 
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the eGFP sequence on days 8 and 14 post-disease induc-
tion. eGFP+ BM-MSCs were detected in the lymph nodes 
of EAE mice at both time points, confirming that these 
cells are capable of homing to sites of inflammation in the 
periphery (Fig. 8B). Significantly, eGFP+ Ad-MSCs were 
detected in the spinal cord 24 h after transplantation as 
well as in the brain and lymph nodes of EAE mice 7 days 
after transplantation. Thus, under neuroinflammatory 
conditions, the broader repertoire of homing molecules 
expressed by Ad-MSCs appears to correlate with an 
enhanced homing capacity in vivo.
DISCUSSION
Since their original identification within the BM com-
partment, MSCs have been identified and characterized 
from a wide variety of tissue sources (18). In comparison 
to BM aspirates, which are attained by an invasive isola-
tion procedure (68), higher cell yields can be obtained 
using safer methods from other sources, such as liposuc-
tioned adipose tissue or discarded umbilical cords. Given 
the abundance of these cellular resources, recent atten-
tion has been directed towards evaluating the applica-
tion of alternative MSC types in a clinical setting for the 
treatment of inflammatory diseases. In the current study, 
human MSCs isolated from three different tissue sources 
were characterized and their therapeutic efficacy evalu-
ated using an EAE model of chronic progressive disease 
induced by rMOG. Our results show a disparity between 
the in vitro immunomodulatory potential of MSCs and 
their clinical effect, highlighting that other functional 
properties, such as the efficiency for homing to sites of 
inflammation, may be critically important to the overall 
efficacy of MSC transplantation.
Comparative MSC studies have revealed differences 
in the proliferative capacity, differentiation potential, cell 
surface phenotype, and immunomodulatory properties of 
tissue-specific MSCs (37,40,55). Evidence presented in 
the current study clearly demonstrated that BM-MSCs 
exerted more potent immunomodulatory effects in vitro 
compared to Ad-MSCs and UC-MSCs, further confirming 
these reports. Only BM-MSCs demonstrated the capac-
ity to modulate T-cell responses through soluble factors 
present in conditioned medium. Two recent reports have 
highlighted the importance of soluble factors released by 
MSCs in mediating clinical recovery. One study showed 
that mouse BM-MSCs ameliorated EAE through the 
paracrine secretion of chemokine (C-C motif) ligand 2 
Table 4. Chemokine Receptor mRNA Expression by MSCs
Chemokine 
Receptor BM-MSC Ad-MSC UC-MSC
CCR1 – + –
CCR2 – – –
CCR3 – – –
CCR4 – – –
CCR5 – – –
CCR6 + + +
CCR7 + + +
CCR8 – – –
CCR9 – + +
CCR10 – + +
CCR11 + + +
CXCR1 – + +
CXCR2 – – –
CXCR3 + + +
CXCR4 – – –
CXCR5 – – –
CXCR6 + + +
CXCR7 + + +
CX3CR1 – – –
CCR, chemokine (C-C motif) receptor; CXCR, chemokine (C-X-C 
motif) receptor; CX3CR1, chemokine (C-X3-C motif) receptor 1.
Figure 7. IFN-g has little effect on chemokine receptor mRNA 
expression by UC-MSCs. Passage 5 UC-MSCs were cultured 
in the presence or absence of 10 ng/ml IFN-g for 72 h, and 
mRNA was extracted in order to detect transcripts for specific 
chemokine receptors. Peripheral blood mononuclear cells were 
used as a positive control. +/–, presence or absence of IFN-g or 
reverse transcriptase (RT) in preparation of cDNA. GAPDH, 
glyceraldehyde 3-phosphate dehydrogenase. See Table 4 for 
chemokine receptor abbreviations.
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(CCL2), which, upon matrix metalloproteinase proteolytic 
processing into an antagonistic derivative, could inhibit 
the function of Th17 cells (62). The other identified hepa-
tocyte growth factor as the major constituent of BM-MSC 
conditioned medium that stimulated remyelination and 
reduced functional deficits when administered to EAE 
mice at the peak of disease (2). 
Our results also revealed that production of the cyto- 
kines TNF-a, IL-6, and IL-10 was significantly upregulated 
when 2D2 splenocytes were cocultured with BM-MSCs 
or BM-MSC conditioned medium. This profile was not 
observed with Ad-MSCs or UC-MSCs, suggesting that 
soluble factors secreted by BM-MSCs may account for 
their potent in vitro immunomodulatory effects. We 
did not identify the mechanism(s) by which BM-MSCs 
induced this cytokine secretion profile, although, given 
the pleiotropic activity of many cytokines, numerous 
pathways may be involved. TNF-a, for example, is often 
considered to be a proinflammatory cytokine but can, para-
doxically, also exert anti-inflammatory effects (48). The 
increase in production of IL-6 and IL-10, which both signal 
through signal transducer and activator of transcription-3 
(45), suggests that BM-MSCs may be modulating Treg 
and Th17 differentiation pathways. Alternatively, the 
suppressive effect exerted by MSCs on T-cells may occur 
indirectly via the modulation of antigen-presenting cell 
function and induction of IL-10 production, as has been 
shown previously (33).
On the basis of our in vitro characterization studies, 
it was predicted that BM-MSCs would have a greater 
therapeutic efficacy when transplanted into an autoimmune- 
mediated disease setting. However, our results showed no 
significant difference in the clinical recovery or suppres-
sion of peripheral T-cell responses in EAE mice treated 
with BM-MSCs, Ad-MSCs, or UC-MSCs. In fact, only 
transplanted Ad-MSCs generated a significant reduc-
tion in disease severity and CNS pathology. The lack of 
correlation between the ability of BM-MSCs to suppress 
immune responses in vitro and the ability to induce clinical 
improvements in vivo has been reported in other disease 
settings, including graft versus host disease (69), collagen-
induced arthritis (66), and experimental autoimmune 
Figure 8. Ad-MSCs are capable of trafficking to the CNS in EAE mice. MSCs were transduced with a lentiviral vector encoding firefly 
luciferase and eGFP. (A) MSCs were transplanted IV in NOD/Lt EAE mice on day 27 postimmunization and the bioluminescence fluc 
signal was examined. Representative images of the distribution of MSCs 48 h after injection are shown. (B) Ad-MSCs and BM-MSCs 
were transplanted into C57Bl/6 EAE mice on day 7 postimmunization. DNA extracted from lymph nodes (LN), spleen (Sp), brain (Br), 
cerebellum (Cb), and spinal cord (SC) on day 8 and day 14 postimmunization was used as a template in PCR reactions using enhanced 
green fluorescent protein (eGFP) or GAPDH-specific primers. DNA from cFMS-GFP mice was used as a positive control (+ve) and 
DNA from uninjected mice was used as a negative control (N). Representative images of one mouse for each time point are shown.
TISSUE-SPECIFIC MSCs FOR TREATMENT OF MS 1421
neuritis (65). To understand why BM-MSCs did not 
potently suppress disease signs in EAE, we explored 
the expression of homing molecules and receptors 
involved in chemotaxis and migration. Overall, we found 
that Ad-MSCs and UC-MSCs expressed a broader rep-
ertoire of homing molecules compared to BM-MSCs. 
All three MSCs lacked expression of P-selectin glyco-
protein ligand-1, which interacts with E- or P-selectin on 
inflamed endothelial cells and mediates the initial tether-
ing and rolling of circulating leukocytes (64). However, 
CD44, which may be an alternative mechanism utilized 
by MSCs for these primary migratory events (10) through 
binding to hyaluronic acid (19), was expressed by all 
three MSCs types. Integrins mediate firm adhesion of cir-
culating cells to endothelial cells via binding membrane-
bound molecules such as VCAM-1 and ICAM-1, which 
are upregulated during inflammation (13). Binding of 
VLA-4 (integrin-a4b1) on migrating T-cells to VCAM-1 
on brain endothelium is important for T-cell extravasa-
tion across the blood–brain barrier, as indicated by the 
efficacy of the blocking antibody natalizumab (12). In 
concert with its effects on T-cells, Pluchino et al. (59) and 
Constantin et al. (14) provided evidence for the impor-
tance of VLA-4 in transplanted neural precursor cells 
and MSCs, respectively, to migrate across the blood–
brain barrier in EAE. We detected integrin-b1 expression 
on all three MSCs, but only Ad-MSCs and UC-MSCs 
expressed integrin-a4. This finding is consistent with 
a previous report demonstrating a lack of surface inte-
grin-a4 expression on BM-MSCs (20), rendering these 
cells incapable of functionally binding to VCAM-1. 
Although the molecular trafficking mechanisms utilized 
by MSCs to home to sites of inflammation in EAE are 
not fully resolved, the lack of integrin-a4 expression by 
the BM-MSCs used in the present study may limit the 
migratory potential and therapeutic efficacy of these 
cells, regardless of their potent immunomodulatory prop-
erties. Indeed, results presented herein examining the fate 
of MSCs in rMOG-EAE revealed that Ad-MSCs were 
capable of trafficking to the spinal cord and brain while 
BM-MSCs were not. Likewise, a recent report demon-
strated that engraftment of MSCs and neural precursor 
cells in a rat model of traumatic brain injury was highly 
dependent on the interaction between integrin-a4 and 
VCAM-1 (49). Expression of integrin-a4 is particularly 
relevant in the current disease setting, given that all three 
MSC types did not express other integrin heterodimers 
important for leukocyte trafficking to inflammatory 
sites in EAE, such as LFA-1 (integrin-aLb2) and Mac-1 
(integrin-aMb2). 
Numerous chemokines and their receptors have been 
implicated in leukocyte trafficking to peripheral lym-
phoid tissues and the CNS in EAE, including CCR1, 
CCR2, CCR5, CCR6, CCR7, CXCR3, and CXCR4 
(35,64). Our analysis of chemokine receptors showed 
that all three MSCs expressed mRNA for CCR6, CCR7, 
CCR11, and CXCR3, while only Ad-MSCs expressed 
CCR1. Other studies have also investigated chemokine 
receptor expression by MSCs, which, together with our 
data, suggest that expression profiles can vary between 
tissue sources and donors. For instance, we did not detect 
expression of CXCR4 mRNA by any of the three MSC 
types. This is consistent with a recent comparison of 
BM-MSCs and UC-MSCs (4), while previous reports 
have demonstrated expression of CXCR4 on MSCs 
(10,36). In addition to donor variability, culture condi-
tions can influence the expression of homing molecules 
and migratory capacity of MSCs. Honczarenko et al. 
(36) found a loss of chemokine receptor expression and 
chemotactic responses of MSCs due to long-term culture 
as well as loss of ICAM-1, ICAM-2, VCAM-1 expres-
sion. Similarly, Tondreau et al. (70) reported a loss of 
VCAM-1 and metalloproteinase expression by MSCs 
between passages 3 and 5. In contrast to these findings, 
we observed no changes in chemokine receptor expres-
sion between passages 3 and 5 MSCs. Exposure to cyto-
kines and growth factors has been shown to upregulate 
homing molecules and stimulate cellular migration. For 
instance, platelet-derived growth factor can increase 
surface expression of CD44 on the rat MSC line Ap8c3 
(76). In the present study, we found that stimulation with 
IFN-g also had very little effect on chemokine receptor 
mRNA expression. Although Hemeda et al. (34) reported 
a similar finding following IFN-g stimulation, exposure 
to TNF-a was shown to regulate MSC migration. Further 
investigations into the regulatory effects of culture con-
ditions and cytokines on MSC migration using multiple 
donors are required. 
Our bioluminescence tracking studies confirmed pre-
vious reports demonstrating that the majority of MSCs 
are arrested in the pulmonary vascular beds following IV 
administration (27). Preclinical animal studies in EAE 
and other disease models have nevertheless indicated that 
clinical improvement does not require high levels of MSC 
engraftment but may often be associated with a “touch-
and-go” effect (72). This may involve direct interactions 
with immune cells and/or paracrine secretion of soluble 
immunomodulatory and trophic factors early after infu-
sion, but with long-lasting effects. The results from our 
transplantation studies revealed that multiple injections 
of MSCs before disease onset led to an improved clinical 
outcome in EAE. The reduced proliferative response of 
splenic T-cells following MSC treatment and the enhanced 
therapeutic effect of high-dose IP Ad-MSC transplanta-
tion in NOD/Lt mice supports a peripheral immunosup-
pressive mechanism of action. Ad-MSCs may have also 
exerted anti-inflammatory effects within the CNS of EAE 
mice, leading to a significant decrease in disease severity 
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compared to PBS-injected controls. Immune modulation 
is, however, not the only mechanism by which MSCs can 
induce clinical recovery in EAE. For instance, paracrine 
secretion of growth factors such as vascular endothelial 
growth factor, insulin-like growth factor, hepatocyte 
growth factor, and fibroblast growth factor by MSCs may 
contribute to antiapoptotic, antioxidant, and antiscarring 
effects (46). 
While the increased efficacy of early MSC treatment 
we observed is consistent with that shown by Zappia et 
al. (75), these results differ from previous reports (14,62), 
in that MSC treatment from the onset of clinical signs 
had no impact on the disease course. This could be due 
to several reasons, such as the use of rMOG to induce 
EAE rather than the encephalitogenic MOG35–55 peptide 
commonly used in other studies. Although disease is ini-
tiated by CD4+ T-cells in both models, antigen-activated 
B-cells produced in rMOG-EAE contribute to disease 
pathogenesis by both humoral and cell-mediated mecha-
nisms. B-cells act as antigen presenting cells to promote 
the differentiation of MOG-specific Th1 and Th17 T-cells 
(73) and are a major source of inflammatory cytokines 
(5). Moreover, antibodies that recognize conformational 
but not linear MOG epitopes can mediate demyelination 
(50). MSCs have been reported to inhibit B-cell function, 
suppressing their proliferation, differentiation, chemo-
taxis, and immunoglobulin production (15). In the present 
study, we show that while the nonspecific and rMOG-
specific proliferative response of splenic T-cells is signifi-
cantly reduced, MSC transplantation appears to have no 
impact on serum rMOG-specific antibody levels in this 
model. Interestingly, in addition to their pathogenic role, 
B-cells may also act as regulators of CNS autoimmunity 
through producing IL-10 and influencing forkhead box 
P3-positive (FoxP3+) Treg homoeostasis (25). Crosstalk 
between MSCs and inflammatory signals received from 
the tissue microenvironment plays an important role in 
directing the nature of the MSC response. For instance, in 
models of Th1/Th17-driven inflammation such as EAE, 
MSCs can induce clinical recovery through suppressing 
Th1/Th17 responses and promoting a Th2 type cytokine 
shift (3,14), whereas their efficacy in Th2-mediated aller-
gic airway inflammation results from the promotion of 
a Th1 phenotype (30). Given the recent concept that 
B-cells may have a dual function in EAE, their interac-
tion with MSCs, and how this bidirectional crosstalk may 
influence pathogenic versus protective B-cell responses 
warrants closer examination. 
The MSC treatment paradigms we investigated collec-
tively suggest that timing as well as cell dose and delivery 
route influence MSC efficacy in rMOG-EAE. MSC trans-
plantation at the onset of disease had no impact on chronic 
progressive EAE, while a single dose before disease onset 
was also not sufficient to alter the clinical course. Using the 
relapsing–remitting model, we found that IP delivery of 
a high Ad-MSC dose prevented disease-related mortality, 
whereas a low IV cell dose did not. Preclinical studies in 
graft versus host disease have also shown that the kinetics 
of MSC delivery is critical to their therapeutic efficacy 
(42). “Licensing” of MSCs by proinflammatory media-
tors, which modulate the MSC secretome and increase 
production of inhibitory and trophic factors, may be nec-
essary in order to achieve beneficial outcomes (42) and 
will be affected by the timing and route of administration. 
Thus, we hypothesize that the low number of IV trans-
planted MSCs that were capable of reaching inflammatory 
sites were not sufficient to attenuate rMOG-EAE severity 
when cells were transplanted later in the disease course or 
at a single dose. Moreover, although MSCs have shown 
efficacy in numerous disease models within the context 
of a xenogeneic transplantation setting, we cannot rule 
out the possibility that clearance of transplanted MSCs by 
the host immune system was a further contributing factor 
that limited their therapeutic effect in rMOG-EAE mice.
In summary, we compared three tissue-specific human 
MSCs and demonstrated that BM-MSCs exerted more 
potent immunomodulatory effects in vitro compared to 
Ad-MSCs and UC-MSCs. Unexpectedly, BM-MSCs did 
not impact the disease course; however, transplantation of 
Ad-MSCs ameliorated clinical signs in two animal models 
of EAE. Significantly, the timing and dose of cell trans-
plantation were found to be the most critical factors that 
led to improved clinical and pathological outcomes. The 
disparity between our in vitro and in vivo findings may 
reflect differences in the homing potential of the MSCs, as 
suggested by differential expression of integrin-a4 and the 
inability of BM-MSCs to traffic to the CNS in the absence 
of this adhesion molecule. While the immunomodulatory 
properties of MSCs play a critical role in mediating the 
amelioration of disease in EAE, the efficiency of MSC 
homing is also likely to be a key determinant of therapeutic 
efficacy (38). Modification of MSCs represents one means 
by which directed homing can be improved. For instance, 
forced expression of integrin-a4, which was absent on the 
BM-MSCs used in this study, improved homing to bone 
in immunocompetent mice (44). Understanding the fate of 
MSCs in vivo and the molecular mechanisms controlling 
their migration will therefore be critical for improving the 
therapeutic efficacy of systemic MSC transplantation for 
the treatment of MS. 
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